Adjuvant ipilimumab for stage III melanoma: the patient voice

Lancet Oncol. 2017 Mar;18(3):282-284. doi: 10.1016/S1470-2045(17)30003-7. Epub 2017 Feb 3.

Authors

Michael Brundage¹, Timothy Hanna²

Affiliations

¹ Cancer Care and Epidemiology, Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada. Electronic address: michael.brundage@krcc.on.ca.
² Cancer Care and Epidemiology, Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada.

PMID: 28163001
DOI: 10.1016/S1470-2045(17)30003-7

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal
Humans
Ipilimumab*
Melanoma*
Skin Neoplasms

Substances

Antibodies, Monoclonal
Ipilimumab